Skip to main content
. 2019 Oct 28;8(11):1330. doi: 10.3390/cells8111330

Figure 2.

Figure 2

si-hVDAC1 treatment markedly reduces cancer stem cell marker expression in U-87MG-derived tumors. (A–D) Immunoblot (A,B) and quantitation (C,D) of protein extracts obtained from U-87MG-derived xenografts treated with si-NT or si-hVDAC1 short (A,C) or long term (B,D), using antibodies specific to the indicated GBM stem cell markers. β-actin is used as an internal loading control. (E,F) mRNA levels of the indicated genes in si-hVDAC1-TTs, relative to those in si-NT-TTs derived from U-87MG tumors subjected to short-term (E) or long-term (F) treatment. All data are expressed as Mean ± SEM, (n = 5 tumors) (* p < 0.05; ** p < 0.01, *** p < 0.001).